Program
sepofarsen
Also written as “QR-110”.
Its studies are mostly in Blindness · Optic Atrophy, Hereditary, Leber, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Laboratoires Thea | 31 open or running | phase 3since Feb 3, 2025 | May 1, 2017 | Nov 2027phase 3 · NCT06891443 |
| ProQR Therapeutics | 21 open or running | phase 3since Feb 21, 2019 | Feb 21, 2019 | none ahead |
Also a collaborator on its studies: sepul-bio.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 1, 2017First study: phase 2 study in Optic Atrophy, Hereditary, LeberNew to Laboratoires TheaLaboratoires Thea · NCT03140969 · 11 enrolled · United States, Belgium
- Feb 21, 2019ProQR Therapeutics's first study: phase 3 study in Leber Congenital Amaurosis 10New to ProQR TherapeuticsProQR Therapeutics · NCT03913143 · 36 enrolled · United States, Belgium, Brazil and more
- Feb 21, 2019Phase 2 study in Leber Congenital Amaurosis 10Laboratoires Thea · NCT03913130 · 9 enrolled · United States, Belgium
- Apr 13, 2021Phase 3 study in Leber Congenital Amaurosis 10ProQR Therapeutics · NCT04855045 · 15 enrolled · Belgium, Brazil, Canada and more
- Feb 3, 2025Phase 3 study in Leber Congenital Amaurosis 10Laboratoires Thea · NCT06891443 · 32 planned · United States, Australia, Belgium and more
Ahead
- Nov 2027Primary completion: phase 3 study in Leber Congenital Amaurosis 10Laboratoires Thea · NCT06891443
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06891443Leber Congenital Amaurosis 10 · United States, Australia, Belgium and more | 3 | Recruiting | Laboratoires Thea | Nov 2027 | 32 |
| NCT04855045Leber Congenital Amaurosis 10 · Belgium, Brazil, Canada and more | 3 | UNKNOWN | ProQR Therapeutics | Dec 2023 | 15 |
| NCT03913143Leber Congenital Amaurosis 10 · United States, Belgium, Brazil and more | 3 | Active, not recruiting | ProQR Therapeutics | Jan 31, 2022 | 36 |
| NCT03913130Leber Congenital Amaurosis 10 · United States, Belgium | 2 | Terminated | Laboratoires Thea | Oct 3, 2022 | 9 |
| NCT03140969Optic Atrophy, Hereditary, Leber · United States, Belgium | 2 | Completed | Laboratoires Thea | Oct 2, 2019 | 11 |
How it is read
Names in the registry
- “sepofarsen”, 3 entries
- “QR-110”, 2 entries
Conditions, from the studies’ own filings
- Blindness, 4 studies
- Optic Atrophy, Hereditary, Leber, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.